Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
The use of chemotherapeutic agents in the treatment of superficial bladder cancer is well known. In particular, mitomycin C (MMC) is globally accepted also in the early treatment after an endoscopic resection. Complications related to MMC are usually scarce as a systemic absorption is quite absent, while its use is effective for the bladder recurrence reduction. In our experience we report a female patient with a bladder perforation after an early instillation of a single dose of MMC. In this case, systemic toxicity occurred requiring subintensive care for a complete repair.
Racioppi
Marco
M
Urology Department, Catholic University School of Medicine, Rome, Italy. mracioppi@tiscali.it
Porreca
Angelo
A
Foschi
Nazario
N
Delicato
Giampaolo
G
Destito
Antonio
A
D'Addessi
Alessandro
A
D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015653:Cystectomy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010535:Laparoscopy; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects*; D012086:Reoperation; D012422:Rupture, Spontaneous / Q000139:chemically induced; D001743:Urinary Bladder / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin